Inhalon Biopharma, Inc.

NC · Founded 2018 · Biotech · Private

Inhaled monoclonal antibody therapeutic delivered via handheld nebulizer for respiratory viral infections

Claim this profile

Follows are private to you and power your alerts

Updated Oct 9, 2026 · inhalon.com

Sector: Biotech
Headquarters: NC
Founded: 2018
Latest Form D: $2M, Aug 2020
Total capital: $17.6M

Federal grants: $10.2M; 10 awards · 2022–2025; Rank in peer group#48 of 479
Private capital raised: $2M; 1 Form D · last Aug 2020; 74 months since last filing
Federal contracts: $5.4M; 2 awards · Defense; Rank in Biotech#77 of 4373
Granted patents: 0; 5 pending

Capital timeline

Latest events

Sep 2025Federal contractDefense · A Phase 1 Placebo-controlled Dose-escalation Safety And Pharmacokinetic Study Of IN-007, A Nebulized, Pan-sars ACE2-DECOY Therapeutic For Pandemic Preparedness$3.2M
Sep 2025Federal grantHealth and Human S · Phase II · Development of IN-003PI as passive immunization against human metapneumovirus infection$1M
Aug 2025Federal grantHealth and Human S · Phase II · Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1M
Jul 2025Federal grantHealth and Human S · Phase II · IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A$1M
May 2025Federal grantHealth and Human S · Phase II · IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1M
Apr 2025Federal grantHealth and Human S · Phase II · SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1M
Sep 2024Federal contractDefense · Developing IN-007 As A Widely Deployable Inhaled Treatment Against Pathogens Utilizing Human ACE2 For Viral Attachment And Entry$2.2M
Aug 2020Private capital raisedForm D · SEC · 1st filing$2M

Show 5 earlier federal awards

Jun 2024Federal grantHealth and Human S · Phase II · Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1M
May 2024Federal grantHealth and Human S · Phase II · IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1M
Mar 2024Federal grantHealth and Human S · Phase II · SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1M
Jun 2023Federal grantHealth and Human S · Phase II · IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1M
Jul 2022Federal grantHealth and Human S · Phase II · IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 479 peers

Line = median

Biotech · Molecule

Federal grants#48 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

John B. WhelanExecutive Officer, DirectorNamed in SEC Form D filings
John B. WhelanExecutive Officer, DirectorNamed in SEC Form D filings
Samuel LaiExecutive Officer, DirectorNamed in SEC Form D filings
Winnie B. WanDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 5

Sep 25, 2025PendingCompositions And Methods For Inhalable TherapeuticsUSPTOApplication 18869268
Feb 16, 2023PendingMethods And Apparatuses For Delivery Of An Agent To The Lungs And Nasal PassagesUSPTOApplication 17889141
PendingCompositions And Methods For Inhalable TherapeuticsUSPTOApplication PCTUS2023067373

Show all 5 patent records

Compositions And Methods For Inhalable TherapeuticsSep 25, 2025 · Application 18869268Pending
Methods And Apparatuses For Delivery Of An Agent To The Lungs And Nasal PassagesFeb 16, 2023 · Application 17889141Pending
Compositions And Methods For Inhalable TherapeuticsApplication PCTUS2023067373Pending
Compositions And Methods For Inhalable TherapeuticsApplication 63345019Pending
Methods And Apparatuses For Delivery Of An Agent To The Lungs And Nasal PassagesApplication 63233661Pending

60 DEGREES PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $5.8M in contracts
FABRICO TECHNOLOGY, INC.Similar federal contract value in Biotech · $5.6M in contracts
Shuttle Pharmaceuticals, Inc.Similar federal contract value in Biotech · $5.5M in contracts
CELL MICROSYSTEMS INCSimilar federal contract value in Biotech · $5.1M in contracts
PLATELET BIOGENESIS, INCSimilar federal contract value in Biotech · $5M in contracts
AUTONOMOUS THERAPEUTICS INCSimilar federal contract value in Biotech · $4.9M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 9, 2026. SBIR and STTR awards through Jul 3, 2026.